Searchable abstracts of presentations at key conferences in endocrinology

ea0075p10 | Pituitary and neuroendocrinology | EYES2021

Hormonal adjustment to metabolic derangement in adult Growth Hormone Deficiency: evaluation of Ghrelin and LEAP-2 serum level

Vergani Edoardo , Bruno Carmine , Curro Diego , Pontecorvi Alfredo , Mancini Antonio

Background: Ghrelin and its endogenous antagonist liver-expressed antimicrobial peptide-2 (LEAP-2) are involved in GH secretion, both acting on GSH-r1α, and regulation of glucose and lipids metabolism. Metabolic impairments are often accompanied by an upregulation of LEAP-2 expression, with a usual concomitant reduction in ghrelin secretion. Adult growth hormone deficiency (aGHD), characterized by weight gain, increased fat mass and insulin resistance, represent a conditi...

ea0081ep826 | Pituitary and Neuroendocrinology | ECE2022

Looking for a safe and effective drug: the troubled journey of a Cushing’s Disease patient

Milioto Angelo , Cocchiara Francesco , Corica Giuliana , Khorrami Keyvan , Nista Federica , Criminelli Diego , Zona Gianluigi , Ferone Diego , Gatto Federico

Cushing’s Disease (CD) is severe clinical condition due to an ACTH-secreting pituitary tumor. Here we present the case of a 25-years old male who came to our attention for hypertension, moon face, acanthosis nigricans, abdominal purple striae and central obesity. The diagnosis of CD was based on the presence of high plasma cortisol after dexamethasone suppression test and elevated urinary free cortisol levels (UFC, 6-fold higher the upper limit of normality (ULN)). The pi...

ea0049ep920 | Neuroendocrinology | ECE2017

Thyroiditis and hypophysitis caused by nivolumab

Fernandez Leticia Perez , Monreal Isabel Azcona , Garcia Maria Martinez , Alaminos Maria Elena Lopez , Aznar Pablo Trincado , Carceller Diana Boj , Ballano Diego Alvarez , Garcia Patricia de Diego

Introduction: Nivolumab is an anti-programmed cell death-1 monoclonal antibody approved for the treatment of metastatic malignant melanoma. Several endocrine disorders have been reported as immune-related adverse effects. However, nivolumab-induced hypophysitis has a lower incidence than ipililumab.Case report: A 69-years old man with metastatic melanoma started to receive nivolumab. Ten weeks after the first cycle of nivolumab he presented hyperthyroidi...

ea0081oc7.5 | Oral Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

Epigenomic and somatic mutation profile of pituitary adenomas (PAs)/ pituitary neuroendocrine tumors (PitNETs)

Guaraldi Federica , Morandi Luca , Zoli Matteo , Righi Alberto , Evangelisti Stefania , Tonon Caterina , Mazzatenta Diego , Asioli Sofia

Background: Pituitary adenomas (PAs)/Pituitary Neuroendocrine Tumors (PitNETs) are a complex and heterogeneous group of lesions. Genetic and epigenetic studies have been performed to identify predictors of treatment outcome.Study aim: To profile clinically non-aggressive (NA) and aggressive (A) PAs/PitNETs, and carcinomas for somatic mutations and epigenetic alterations of genes involved in cell proliferation/differentiation, miRNA/lncRNA-post-transcript...

ea0081p407 | Pituitary and Neuroendocrinology | ECE2022

Endoscopic surgery for acromegaly: results and predictors of outcome from a 22-year experience of a referral Pituitary Centre

Guaraldi Federica , Zoli Matteo , Gori Davide , Cavicchi Riccardo , Pasquini Ernesto , Sollini Giacomo , Asioli Sofia , Mazzatenta Diego

Background: Endoscopic surgery (ES) performed in Pituitary Centers of Excellence (PCOE) represents the gold standard treatment for GH-secreting adenomas. However, rate of cure greatly varies according to definition criteria, follow-up duration, various patient and adenoma features, and surgeon ability.Study aim: To assess short- (3 month) and long-term (≥1 year) outcome and identify predictors of ES, in a large and homogeneous cohort of acromegaly ...

ea0081ep677 | Pituitary and Neuroendocrinology | ECE2022

Role of new peptide biomarkers in metabolic profiling of adult growth hormone deficiency patients: preliminary data on neudesin and its relationship with LEAP-2

Vergani Edoardo , Bruno Carmine , Gavotti Cesare , Oliva Alessandro , Curro Diego , Mancini Antonio

Patients affected by adult growth hormone deficiency (aGHD) show worse metabolic profile, with insulin-resistance, increased total cholesterol, LDL, triglycerides, reduced HDL, and higher risk of developing type 2 diabetes mellitus and cardiovascular complications. Adult GHD and metabolic syndrome (MetS) are closely related to each other, since they share the previous depicted clinical features, while obese MetS patients display lower IGF-1 levels due to a functional reduction...

ea0090ep247 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Intake of alpha-lipoic acid (thioctic acid) and insulin autoinmune syndrome. A case report

Urzaiz Leticia Serrano , Trincado Pablo , Diego Patricia De , Gonzalez Wendy Valeria , Lacarta Macarena , Moreno Carlos

A 52-year-old female patient with no previous history of interest, and with no prescribed habitual chronic treatment, was admitted to our hospital to be studied for symptomatic hypoglycemias of one month of evolution. Symptoms consisted of malaise, hunger, tremors and profuse sweating that disappeared with food ingestion. She referred hypoglycemic (up to 40 mg/dl) episodes daily, both in fasting and postprandial periods. She even suffered nocturnal episodes that woke her up. O...

ea0090ep721 | Pituitary and Neuroendocrinology | ECE2023

An international, simulated-use study assessing nurses’ preferences between two lanreotide syringes (Somatuline Autogel vs Pharmathen) for treatment of neuroendocrine tumours (NETs) and/or acromegaly: PRESTO 3

Ferone Diego , Martin Wendy , Williams Jessica , Houchard Aude , Pommie Christelle , Ribeiro-Oliveira Antonio , Grossman Ashley B

Introduction/Background: Patients with NETs and acromegaly are commonly treated with somatostatin analogues (SSAs), such as octreotide and lanreotide depot formulations. The Pharmathen syringe is now available in several European countries and the USA for lanreotide depot injection. When using SSAs, confidence in and ease of use with syringes is important for decision-making in long-term therapy.Aims: PRESTO 3 compared nurses’ preference for the Som...

ea0063p1115 | Pituitary and Neuroendocrinology 3 | ECE2019

Pituitary apoplexy occurs more frequently in the morning

Faustini-Fustini Marco , Guaraldi Federica , Zoli Matteo , Asioli Sofia , Mazzatenta Diego , Provini Federica

Pituitary apoplexy (PA) is a rare clinical syndrome due to sudden haemorrhage and/or infarction of the pituitary gland, usually within a pre-existent pituitary tumour. Even though some sporadic cases of PA associated with rare sellar lesions (such as Rathke cleft cysts) have been reported, in the vast majority of cases the syndrome occurs within a pituitary adenoma. At presentation, patients with PA usually complain of sudden and severe headache, often associated with visual l...

ea0049ep886 | Growth hormone IGF axis - basic | ECE2017

Nodular thyroid disease in acromegaly: cohort of 69 patients at a single institution

Alvarez-Escola Cristina , Gonzalez Diego Meneses , Dominguez Oscar Moreno , de la Morena Lucrecia Herranz

Materials and methods: The aims were to evaluate the frequency of nodular thyroid disease (NTD) in acromegalic patients and to correlate clinical and metabolic features with disease activity and other. We conducted a cross-sectional study including retrospectively 69 acromegalic patients attending to an University Hospital in Madrid, Spain between 1980 and 2016. Mean age was 63 (32–92) years, 63.8% of patients were female. Mean age at diagnosis of acromegaly was 48 (11&#1...